Hims, Super Bowl and Hers
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
BJP MLA Vijender Gupta on Thursday urged Lieutenant Governor VK Saxena to implement the PM-ABHIM and the HIMS schemes in Delhi to help revive the city’s struggling public healthcare system. In a ...
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results